Vontobel Holding Ltd. Makes New $68,000 Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Vontobel Holding Ltd. purchased a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 15,723 shares of the company’s stock, valued at approximately $68,000.

A number of other hedge funds have also recently made changes to their positions in BDTX. Susquehanna Fundamental Investments LLC bought a new position in Black Diamond Therapeutics in the 1st quarter valued at about $82,000. Acadian Asset Management LLC raised its stake in shares of Black Diamond Therapeutics by 13.8% in the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after purchasing an additional 20,616 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Black Diamond Therapeutics in the second quarter valued at approximately $108,000. Bank of New York Mellon Corp bought a new position in shares of Black Diamond Therapeutics in the second quarter valued at approximately $508,000. Finally, Rhumbline Advisers boosted its position in shares of Black Diamond Therapeutics by 10,334.3% during the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock valued at $218,000 after buying an additional 46,401 shares during the last quarter. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Black Diamond Therapeutics Stock Performance

NASDAQ BDTX opened at $3.06 on Thursday. The company has a market capitalization of $172.13 million, a PE ratio of -1.84 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 52-week low of $1.62 and a 52-week high of $7.66. The company has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $5.19.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts forecast that Black Diamond Therapeutics, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BDTX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, October 9th. Wedbush reissued an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th. Piper Sandler increased their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Finally, Raymond James began coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 target price for the company.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.